Assignee
ADAPTIMMUNE LTD
GB·21 granted patents·28 pending applications·28 citations·filing 2014–2024
Top patents by PatentIndex Score
49 records- 0191US11286289B2T cell receptorsADAPTIMMUNE LTD·Filed 2018·Granted Mar 29, 2022·6 cites·13 claims
- 0290US9822163B2High affinity NY-ESO T cell receptorsADAPTIMMUNE LTD·Filed 2016·Granted Nov 21, 2017·3 cites·4 claims
- 0388US9279122B2T cell receptor displayADAPTIMMUNE LTD·Filed 2014·Granted Mar 8, 2016·5 cites·5 claims
- 0487US9512197B2High affinity NY-ESO T cell receptorsADAPTIMMUNE LTD·Filed 2015·Granted Dec 6, 2016·2 cites·3 claims
- 0586US2025084146A1T cell receptorsADAPTIMMUNE LTD·Filed 2024·Application pending·0 cites
- 0683US12180260B2T cell receptorsADAPTIMMUNE LTD·Filed 2023·Granted Dec 31, 2024·0 cites·21 claims
- 0782US12145990B2T cell modification and use thereofADAPTIMMUNE LTD·Filed 2021·Granted Nov 19, 2024·1 cites·19 claims
- 0881US9447410B2T cell receptor displayADAPTIMMUNE LTD·Filed 2014·Granted Sep 20, 2016·2 cites·11 claims
- 0980US11111301B2T cell modification and use thereofADAPTIMMUNE LTD·Filed 2018·Granted Sep 7, 2021·2 cites·18 claims
- 1079US11572400B1T cell receptorsADAPTIMMUNE LTD·Filed 2022·Granted Feb 7, 2023·0 cites·12 claims
- 1177US2025122263A1T cell receptorsADAPTIMMUNE LTD·Filed 2024·Application pending·0 cites
- 1276US12180261B2T cell receptorsADAPTIMMUNE LTD·Filed 2023·Granted Dec 31, 2024·0 cites·20 claims
- 1375US11725040B2T cell receptorsADAPTIMMUNE LTD·Filed 2021·Granted Aug 15, 2023·0 cites·12 claims
- 1475US2021061878A1High affinity ny-eso t cell receptorsADAPTIMMUNE LTD·Filed 2020·Application pending·0 cites
- 1574US2025043011A1T Cell Modification and Use ThereofADAPTIMMUNE LTD·Filed 2024·Application pending·0 cites
- 1671US11203627B2T cell receptorsADAPTIMMUNE LTD·Filed 2017·Granted Dec 21, 2021·2 cites·17 claims
- 1771US9976121B2T cells with increased immunosuppression resistanceADAPTIMMUNE LTD·Filed 2017·Granted May 22, 2018·3 cites·5 claims
- 1870US11753456B2T cell receptorsADAPTIMMUNE LTD·Filed 2021·Granted Sep 12, 2023·0 cites·18 claims
- 1968US12060404B2T cell receptorsADAPTIMMUNE LTD·Filed 2022·Granted Aug 13, 2024·0 cites·12 claims
- 2066US2018072788A1High affinity ny-eso t cell receptorsADAPTIMMUNE LTD·Filed 2017·Application pending·0 cites
- 2165US11084862B2T cell receptorsADAPTIMMUNE LTD·Filed 2019·Granted Aug 10, 2021·0 cites·6 claims
- 2265US10344074B2T cell receptorsADAPTIMMUNE LTD·Filed 2016·Granted Jul 9, 2019·1 cites·17 claims
- 2365US2021324036A1T cell receptorsADAPTIMMUNE LTD·Filed 2021·Application pending·0 cites
- 2463US11739442B2TCR librariesADAPTIMMUNE LTD·Filed 2021·Granted Aug 29, 2023·0 cites·4 claims
- 2563US2023133064A1T cell manufacturing processADAPTIMMUNE LTD·Filed 2022·Application pending·0 cites
- 2662US2024327791A1Methods of t cell productionADAPTIMMUNE LTD·Filed 2022·Application pending·0 cites
- 2762US2019144521A1T cell receptorsADAPTIMMUNE LTD·Filed 2018·Application pending·0 cites
- 2861US2015231202A1High affinity ny-eso t cell receptorsADAPTIMMUNE LTD·Filed 2015·Application pending·0 cites
- 2960US2024124841A1Methods of producing haemogenic endothelial cells from pluripotent stem cellsADAPTIMMUNE LTD·Filed 2022·Application pending·0 cites
- 3058US2024374728A1T Cell ModificationADAPTIMMUNE LTD·Filed 2024·Application pending·0 cites
- 3158US2025375520A1Production of immune cellsADAPTIMMUNE LTD·Filed 2023·Application pending·0 cites
- 3257US2025367289A1Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonistADAPTIMMUNE LTD·Filed 2023·Application pending·0 cites
- 3356US10689620B2T cells with increased immunosuppression resistanceADAPTIMMUNE LTD·Filed 2018·Granted Jun 23, 2020·0 cites·17 claims
- 3456US2022370559A1Method of treatment of cancer or tumourADAPTIMMUNE LTD·Filed 2022·Application pending·0 cites
- 3555US11124556B2TCR librariesADAPTIMMUNE LTD·Filed 2016·Granted Sep 21, 2021·0 cites·16 claims
- 3655US2023190802A1Method of treatment of cancer or tumourADAPTIMMUNE LTD·Filed 2021·Application pending·0 cites
- 3754US2019135892A1T cell receptorsADAPTIMMUNE LTD·Filed 2018·Application pending·0 cites
- 3853US9932597B2Vectors for transgene expressionADAPTIMMUNE LTD·Filed 2014·Granted Apr 3, 2018·1 cites·21 claims
- 3951US2024392244A1Modification of cells with heterologous t-cell receptor (tcr) coding sequencesADAPTIMMUNE LTD·Filed 2022·Application pending·0 cites
- 4049US2023190803A1Method of treatment of cancer or tumourADAPTIMMUNE LTD·Filed 2021·Application pending·0 cites
- 4145US2022275395A1Lentiviral transduction methodsADAPTIMMUNE LTD·Filed 2020·Application pending·0 cites
- 4245US2022267729A1Methods of t cell productionADAPTIMMUNE LTD·Filed 2020·Application pending·0 cites
- 4345US2024016853A1Modified ipscsADAPTIMMUNE LTD·Filed 2021·Application pending·0 cites
- 4442US2023390334A1Method of treatment of cancer or tumourADAPTIMMUNE LTD·Filed 2021·Application pending·0 cites
- 4540US2022275332A1T cell production from rag inactivated ipscsADAPTIMMUNE LTD·Filed 2020·Application pending·0 cites
- 4639US2022267733A1Methods of producing haemogenic progenitor cells from pluripotent stem cellsADAPTIMMUNE LTD·Filed 2020·Application pending·0 cites
- 4739US2022275335A1Culture medium for haematopoietic inductionADAPTIMMUNE LTD·Filed 2020·Application pending·0 cites
- 4833US2020032208A1Methods of Isolating Naive Regulatory T CellsADAPTIMMUNE LTD·Filed 2018·Application pending·0 cites
- 4931US2022042991A1Viral Assay MethodADAPTIMMUNE LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ADAPTIMMUNE LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →